Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen.
Cortinovis
Monica
M
Gotti
Eliana
E
Remuzzi
Giuseppe
G
Perico
Norberto
N
Cattaneo
Dario
D
Baldelli
Sara
S
D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D004359:Drug Therapy, Combination; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use*; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011494:Protein Kinases / Q000009:adverse effects; D012189:Retrospective Studies; D020123:Sirolimus / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases
D065692:Cytochrome P-450 CYP3A Inhibitors; D015525:Fatty Acids, Omega-3; D005231:Fatty Acids, Unsaturated; D007166:Immunosuppressive Agents; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus